S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Cytologically or pathologically verified cancer that is of advanced stage and for which there is no effective therapy

  * No lymphoma
* Measurable or nonmeasurable disease
* Previously irradiated (whole brain or gamma knife) brain metastases allowed provided there is no requirement for corticosteroids or anticonvulsants

PATIENT CHARACTERISTICS:

* Zubrod performance status 0-2
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 9 g/dL (without transfusions)
* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver metastases present)
* Bilirubin normal
* Serum creatinine ≤ 1.5 times ULN OR measured creatinine clearance OR calculated creatinine clearance ≥ 60 mL/min
* QTC interval \< 480 msec on baseline ECG OR average QTC \< 480 msec on baseline plus 2 additional screening ECG's
* Fasting cholesterol \< 350 mg/dL
* Fasting triglycerides \< 400 mg/dL
* No uncontrolled hypertension, arterial thrombotic event, or bleeding on therapeutic anticoagulation with warfarin or heparin (including low molecular weight heparin) within the past 6 months
* Able to swallow enteral medications
* No feeding tubes
* No intractable nausea or vomiting
* No gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn, ulcerative colitis)
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to rapamycin analogs (e.g., sirolimus and everolimus)
* No known HIV positivity
* No uncontrolled intercurrent illness including, but not limited to, the following:

  * Ongoing or serious active infection
  * Symptomatic congestive heart failure
  * Unstable angina pectoris
  * Serious cardiac arrhythmia
  * History of myocardial infarction
  * Cerebrovascular accident within 3 months of study entry
  * Uncontrolled diarrhea
  * Psychiatric illness or social situation that would limit compliance with study requirements
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception, including barrier methods
* Willing to undergo pharmacokinetic (PK) sampling and blood submission for PK and translational medicine studies

PRIOR CONCURRENT THERAPY:

* Recovered from all prior therapy
* No prior pazopanib hydrochloride or temsirolimus
* More than 28 days since prior major surgery, chemotherapy, biologic therapy, or immunotherapy
* More than 28 days since prior investigational agents
* At least 14 days since prior radiotherapy
* No concurrent rapamycin (sirolimus)
* No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), CYP3A4 inducers (e.g., rifampin or St. John's wort), or CYP3A4 inhibiting agents or substrates (e.g., ketoconazole, diltiazem, or verapamil)
* No concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other type of therapy for treatment of this cancer while on this protocol

  * No live vaccines
  * Luteinizing-hormone releasing-hormone agonists allowed
* Concurrent prophylactic warfarin (≤ 1 mg/day) allowed
* Concurrent bisphosphonate or erythropoietin or its analogue allowed, if deemed appropriate by the treating physician